Capula Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Capula Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$848K	Buy	1,900 +1,500	+375%	+$699K	0.01%	390
2025 Q4	$181K	Sell	400 -3,600	-90%	-$1.55M	﹤0.01%	611
2025 Q3	$1.57M	Buy	4,000 +3,700	+1,233%	+$1.55M	0.01%	291
2025 Q2	$134K	Sell	300 -200	-40%	-$92.2K	﹤0.01%	459
2025 Q1	$242K	Buy	+500	New	+$233K	﹤0.01%	475
2024 Q4	–	Sell	-300	Closed	-$140K	–	621
2024 Q3	$140K	Buy	+300	New	+$144K	﹤0.01%	429
2023 Q1	–	Sell	-10,100	Closed	-$2.92M	–	944
2022 Q4	$2.92M	Sell	10,100 -30,000	-75%	-$9.14M	0.04%	321
2022 Q3	$11.6M	Buy	+40,100	New	+$11.5M	0.16%	160
2021 Q2	–	Sell	-9,500	Closed	-$2.04M	–	887
2021 Q1	$2.04M	Hold	9,500	–	–	0.04%	295
2020 Q4	$2.25M	Buy	9,500 +7,500	+375%	+$1.72M	0.11%	165
2020 Q3	$544K	Sell	2,000 -8,000	-80%	-$2.21M	0.07%	113
2020 Q2	$2.9M	Buy	+10,000	New	+$2.71M	0.1%	180
2020 Q1	–	Sell	-29,300	Closed	-$6.42M	–	460
2019 Q4	$6.42M	Sell	29,300 -5,000	-15%	-$1.01M	0.14%	147
2019 Q3	$5.81M	Buy	+34,300	New	+$6.07M	0.12%	158

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capula Management's VRTX Position: Q1 2026 in Review

Capula Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 247 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #875 among its holdings. This is a return to the name: Capula Management previously reported a position in VRTX as recently as Q3 2025.

Capula Management first reported a position in VRTX in Q3 2019 and has held it in 13 quarters since. The position peaked at $1.63M in Q3 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Capula Management held 247 shares of Vertex Pharmaceuticals worth $110K as of Q1 2026.
Vertex Pharmaceuticals was a new Capula Management position in Q1 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Capula Management's portfolio in Q1 2026, its #875 holding.
Capula Management first reported a position in Vertex Pharmaceuticals in Q3 2019 and has held it in 13 quarters since.
Capula Management's Vertex Pharmaceuticals position peaked at $1.63M in Q3 2021.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Capula Management's 13F filing for Q1 2026, filed 14 May 2026.